Development of expression-based biomarkers of Dasatinib response in hematologic malignancies

Blood Cancer J. 2017 Dec 15;7(12):652. doi: 10.1038/s41408-017-0013-z.

Authors

Monica K Akre¹, Amit Mitra¹, Wen Wang², Chad L Myers², Brian Van Ness³

Affiliations

¹ Department of Molecular, Cellular, Developmental Biology, and Genetics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.
² Department of Computer Science and Engineering, University of Minnesota, Minneapolis, MN, 55455, USA.
³ Department of Molecular, Cellular, Developmental Biology, and Genetics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA. vanne001@umn.edu.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Algorithms
Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / analysis*
Biomarkers, Tumor / genetics
Dasatinib / therapeutic use*
Drug Resistance, Neoplasm / genetics*
Gene Expression Profiling / methods*
Hematologic Neoplasms / drug therapy*
Hematologic Neoplasms / genetics
Humans
Treatment Outcome

Substances

Antineoplastic Agents
Biomarkers, Tumor
Dasatinib